| New from NCI |
| Prescription Aid Helps Women with Early-Stage Breast Cancer |
 |
|
Results of a new study show that subsidies for prescription drugs can increase the use of hormone therapies among women with early-stage breast cancer and may also help to decrease racial and ethnic differences in the use of these medications. |
| No Safe Level of Smoking |
 |
|
A new study from NCI researchers shows that people who consistently smoked an average of less than one cigarette per day over their lifetimes had a 64 percent higher risk of earlier death than people who never smoked.
|
|
Another Immunotherapy Drug Approved for Head and Neck Cancer
The Food and Drug Administration (FDA) has approved another immunotherapy drug to treat squamous cell cancer of the head and neck. This NCI Cancer Currents blog post explains the study that led to this approval.
|
|
Immune-Cell Traps May Aid Metastasis
A new study suggests that cancer cells may use a normal function of neutrophils, the most common form of white blood cell, to help form metastatic tumors. Researchers from Cold Spring Harbor Laboratory in New York believe this study may help fill in some of the gaps in what is known about this process.
|
| PDQ Summary Updates |
|
Childhood Rhabdomyosarcoma Treatment
This revision of the PDQ summary includes updates to information on diagnostic tests, risk groups, treatment options, and the treatments used for rhabdomyosarcoma in different parts of the body.
|
|
Neuroblastoma Treatment
We’ve updated the entire PDQ summary, including updates to the treatment options for neuroblastoma and the treatments used for different stages and risk groups.
|
|
Unusual Cancers of Childhood Treatment
We’ve added a new section on intraocular (eye) melanoma to our PDQ summary on unusual childhood cancers.
|
| Drug Information Updates |
|
New Approval for Multiple Myeloma
We’ve updated our daratumumab summary to include a recent approval from the FDA. Daratumumab is now approved to be used with two other drugs to treat multiple myeloma in patients who have already received one other treatment.
|
